To help identify clinical considerations for the use of UPTRAVI® (selexipag) in patients with pulmonary arterial hypertension (PAH),5 this interactive simulation features three hypothetical patients: a 53-year-old female diagnosed with idiopathic PAH, WHO FC II; a 28-year-old undiagnosed female presenting with symptoms of PAH; and a 46-year-old male diagnosed with idiopathic PAH, WHO FC III.
The goal of this program is to reinforce the clinical significance of objective risk assessment in patients with PAH and to explore different treatment approaches consistent with the 2022 European Society of Cardiology (ESC) and European Respiratory Society (ERS) Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension (PH).1
Dr. Bindu Akkanti, Associate Professor of Medicine at UTHealth in Houston, will guide you through these three hypothetical patients’ journeys.
This promotional educational activity is brought to you by the Janssen Pharmaceutical Companies of Johnson & Johnson and is not certified for continuing medical education. The consultant is a paid speaker for Janssen. The speaker is presenting on behalf of Janssen and must present information in compliance with FDA requirements applicable to Janssen.
References:
- Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2023;61(1):2200879. doi:10.1183/13993003.00879-2022
- Benza RL, Kanwar MK, Raina A, et al. Development and Validation of an Abridged Version of the REVEAL 2.0 Risk Score Calculator, REVEAL Lite 2, for Use in Patients With Pulmonary Arterial Hypertension. Chest. 2021;159(1):337-346. doi:10.1016/j.chest.2020.08.2069
- Vachiéry JL, Gaine S. Challenges in the diagnosis and treatment of pulmonary arterial hypertension. Eur Respir Rev. 2012;21(126):313-320. doi:10.1183/09059180.00005412
- Ryan JJ, Melendres-Groves L, Zamanian RT, et al. Care of patients with pulmonary arterial hypertension during the coronavirus (COVID-19) pandemic. Pulm Circ. 2020;10(2):1-7. doi:10.1177/2045894020920153
- UPTRAVI® Full Prescribing Information. Actelion Pharmaceuticals US, Inc.
© 2023 Actelion Pharmaceuticals US, Inc. cp-374525v1 08/23